BROMOCRIPTINE VERSUS PLACEBO IN LEVODOPA TREATED PATIENTS WITH PARKINSON'S DISEASE

Publisher Website
Google Scholar
Abstract
Patients (20) with idiopathic parkinsonism who were on optimal L-dopa therapy for at least 3 mo. prior to the investigation and where the effect of the treatment was decreasing or side effects were increasing, were treated with bromocriptine in a double-blind crossover trial during a 12 + 12 wk period. Reduction in disability scores apparently was significant. Hyperkinesia was more frequent in the bromocriptine period than in the placebo period, but reduction of dose in 6 patients for this reason was not followed by deterioration. Both hyperkinesia and other side effects disappeared after dose reduction. Doses were 2.5 mg-40 mg. Bromocriptine seems a valuable supplement to previous therapy in these patients.